Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

Antibodies to watch in 2024
Silvia Crescioli, Hélène Kaplon, Alicia M. Chenoweth, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 89
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E. Sands, Geert R. D’Haens, David B. Clemow, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 12, pp. 2245-2258
Open Access | Times Cited: 17
The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease
Aleksandra Korta, Julia Kula, Krzysztof Gomułka
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10172-10172
Open Access | Times Cited: 30
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme
Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Bruce E. Sands, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 8, pp. 1270-1282
Open Access | Times Cited: 14
Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions
Marla C. Dubinsky, Alison Potts Bleakman, Remo Panaccione, et al.
The American Journal of Gastroenterology (2023) Vol. 118, Iss. 11, pp. 1940-1953
Open Access | Times Cited: 22
Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease
Zhezhe Tian, Qiaorui Zhao, Xiu Teng
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E. Sands, Geert R. D’Haens, David B. Clemow, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 7
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme
Silvio Danese, Axel Dignaß, Katsuyoshi Matsuoka, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 11, pp. 1845-1856
Open Access | Times Cited: 5
Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent advances
Michael Colwill, Jennifer Clough, Samantha Baillie, et al.
Frontline Gastroenterology (2025), pp. flgastro-102830
Closed Access
Treatment targets in IBD: is it time for new strategies?
Fabrizio Fanizzi, Ferdinando D’Amico, Laurent Peyrin‐Biroulet, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101990-101990
Closed Access
Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease
Tadakazu Hisamatsu, Jun Miyoshi, Minoru Matsuura
Internal Medicine (2025)
Open Access
Bowel urgency in ulcerative colitis assessed from patients’ reports: Results of a telemonitoring programme
E. Carboni, F Stalla, Marco Mendolaro, et al.
Digestive and Liver Disease (2025)
Open Access
Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies
Millie D. Long, Stefan Schreiber, Toshifumi Hibi∥, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey
Nadia Wespi, Stephan R. Vavricka, Stephan Brand, et al.
United European Gastroenterology Journal (2024)
Open Access | Times Cited: 2
Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review
W. D. Tan, Zi-xuan Liu, Xiaoyan Liu, et al.
Pain and Therapy (2024) Vol. 13, Iss. 6, pp. 1447-1469
Open Access | Times Cited: 2
Fecal Urgency in Ulcerative Colitis: Impact on Quality of Life and Psychological Well-Being in Active and Inactive Disease States
Gaurav Nigam, Jimmy K. Limdi, Sebastian Bate, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 8, pp. 1731-1733.e2
Open Access | Times Cited: 6
Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis
David Choi, H Sheridan, Shubha Bhat
Annals of Pharmacotherapy (2024) Vol. 58, Iss. 11, pp. 1134-1139
Closed Access | Times Cited: 1
The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis
Lushen Pillay, Sreedhar Subramanian
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 11, pp. 2238-2239
Closed Access | Times Cited: 1
Insights into disability and psycho-social care of patients with inflammatory bowel disease
Olga Maria Nardone, Giulio Calabrese, Alessia La Mantia, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
Hans Herfarth, Anita Afzali, Monika Fischer, et al.
Clinical and Translational Gastroenterology (2023) Vol. 15, Iss. 3, pp. e00669-e00669
Open Access | Times Cited: 1
Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases
Theodora Claudia Gheonea, Mária Bogdán, Andreea-Daniela Meca, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Page 1

Scroll to top